|
(11) | EP 0 472 325 A2 |
| (12) | EUROPEAN PATENT APPLICATION |
|
|
|
|
|||||||||||||||||||||||||||
| (54) | Acid addition salts of an optically active alaninanilide compound and pharmaceutical compositions containing the same |
| (57) Acid addition salts of an optically active alaninanilide compound represented by
the formula:
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group; and the carbon atom marked with (R) means a carbon atom in a form of R-configuration, and pharmaceutical compositions containing such a salt. The salts are useful as drugs for treatment of arrhythmias, thombosises or ischemic cardiac insufficiencies. |
[0001] The present invention relates to acid addition salts of an optically active alaninanilide compound.
[0002] A pharmacologically active alaninanilide compound having an asymmetic carbon atom has been used in the form of a racemic mixture as an active ingredient. More recently an optically active compound of the pharmacological active compound has been preferably used as an active ingredient to avoid side effects.
[0003] U.S. Patent No. 4,696,930 discloses substituted aniline compounds represented by the formula:
wherein R₁ is alkylene′-NH₂ or alkylene′-A′; R₂, R₃ and R₄ are, independently, a hydrogen atom or a methyl group; A and A′ are independently, an unsubstituted or a lower alkyl or an aryl substituted pyridinyl, or pyrimidinyl group; alkylene and alkylene′ are independently, straight chain alkylene moieties of 1-5 carbon atoms optionally substituted with one or more alkyl substituents of 1-5 carbon atoms, or when an asymmetric carbon is present, an enantiomer thereof, or a racemic mixture thereof; or a pharmaceutically acceptable salt thereof being useful as antiarrhythmic agents.
[0004] In that document, rac.-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide represented by the formula:
which is closely related to the salts of the present invention is actually described. However, the compound of the formula (IV) above is a racemate not an optically active compound.
[0005] An optically pure alaninanilide compound in the free form of formula (IV) is an oily substance, therefore it is very hard to formulate such an optically pure compound in a pharmaceutical composition.
[0006] Furthermore, a hydrochloric acid salt thereof has a highly hygroscopic property, and the water contained in such a salt varies depending upon the moisture in atmosphere in which that salt is allowed to stand. In an atmosphere of high humidity, such a salt is deliquesced.
[0007] Accordingly, the net weight of that salt tends to vary due to its hygroscopic property of absorbing moisture from atmosphere. Taking into consideration the fact that a pharmaceutical composition has always to contain an active agent at a prescribed ratio so as to achieve the expected effect and safety, such a salt is not necessarily desirable for preparing pharmaceutical compositions.
[0008] The present invention provides an acid addition salt of an optically alaninanilide compound of formula (I) below useful for drugs.
[0009] The present invention further provides a pharmaceutical composition containing a salt of an optically active alaninanilide compound as an active ingredient.
[0010] In accordance with the present invention there is provided an acid addition salt of an optically active alaninanilide compound represented by the formula:
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group; and the carbon atom marked with (R) means a carbon atom in the R-configuration.
[0011] Our extensive research and experimentation has shown that the salts of the formula (I) above absolutely solve the problems of the prior art compound and salts. That is, the salts of the formula (I) are non-hygroscopic and thus have a constant net weight and are stable without being affected by moisture contained in the atmosphere. They are stable in an atmosphere having about 50% relative humidity at about 25-26°C. They can thus advantageously be used to formulate pharmaceutical compositions which can be of high quality.
[0012] The acid addition salts of an optical active alaninanilide compound represented by formula (I) of the present invention exhibit anti-arrhythmic activities, thromboxane A₂-synthetase inhibitory activities and platelet aggregation inhibitory activities in the same way as does a racemate of formula (IV) or an acid addition salt thereof. Thus they are useful as drugs for the treatment of arrhythmias, thrombosises or ischemic cardiac insufficiencies.
[0013] The acid addition salts of formula (I) of the present invention can be prepared by treating a free amine of an optically active alaninanilide compound or a racemate with an optical active tartaric acid derivative such as D-tartaric acid, dibenzoyl-D-tartaric acid, or ditoluoyl-D-tartaric acid, and then, if necessary, by fractional crystallization of the obtained crude acid addition salt in accordance with the usual manner.
[0014] The compound of formula (IV) can be prepared in a similar way to that described in the aforementioned U.S. Patent 4,696,930.
[0015] For example, N-carboethoxyphthalimide is reacted with alanine to obtain 2-phthalimidopropionic acid, and the reaction product is converted to a reactive functional derivative thereof, such as acid chloride. The acid chloride is then reacted with N-[3-(3-pyridyl)-propyl]-2,6-dimethylaniline to obtain 2-phthalimido-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]-propanamide and then the product is treated with a base, such as methylamine to prepare the desired product of the formula (IV).
[0016] In the preparation of the compound of formula (IV) described above, if the optically active D-alanine is employed as a starting material, a desired optically active compound can be obtained in high purity. If that prepared compound is then employed as the starting material to prepare an acid addition salt of formula (I), the desired acid addition salt can be purified from the obtained crude acid addition salt by a very simple purification manner.
[0017] In the present invention the acid addition salt, (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]-propanamide D-tartrate represented by the formula (II):
wherein the carbon atom marked with (R) has the same meaning as described above, is the most preferred.
[0018] When the acid addition salts of formula (I) of the present invention are employed in the treatment of a patient, any pharmaceutical compositions containing the compound as an active ingredient, such as tablets, capsules, powders, granules, syrups and injectable preparations, may be formulated and may be administered orally or parenterally. These pharmaceutical compositions can be formulated in accordance with usual formulation manners.
[0019] The dosage of the compound may be determined in accordance with sex, age and body weight of a patient, the nature of the disease and the degree of illness. It may, for example, be 1-100 mg per day in oral administration in the adult and 0.1-1000 mg per day in parenteral administration in the adult.
[0020] The present invention is further illustrated by way of the following Examples and Reference Examples. The melting points of the products obtained were uncorrected. The optical purities of the products were calculated by chiral HPLC [Column: SUMICHIRAL OA-4600 (Sumitomo Chemical Co., Ltd.) 5 µm, 4 mm i.d. x 25 cm; Eluent: n-hexane : dichloroethane : ethanol = 80:15:5; Flow rate: 1.0 ml/min; Detection: UV 260 nm]. Samples were treated with acetic anhydride to derive acetates thereof prior to the chromatography.
Reference Example 1
(R)-2-Phthalimidopropionic acid
[0022] To a solution of 50 g of D-alanine in 500 ml of water, was added 78 ml of triethylamine, and 123 g of N-carbethoxyphthalimide was added to the mixture in small portions under ice-cooling. The mixture was stirred for the following 30 minutes. The precipitated materials were filtered off and the filtrate was acidified to pH 1-2 with 6N-hydrochloric acid and was cooled to 5°C to precipitate crystals. The crystals were collected by filtration and were washed twice each time with 100 ml of water and dried at 40°C under reduced pressure to give 93 g of (R)-2-phthalimidopropionic acid as white crystals.
Reference Example 2
(R)-2-Phthalimido-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide hydrochloride
[0023] To a suspension of 10 g of (R)-2-phthalimido-propionic acid in 10 ml of thionyl chloride was added 1.8 ml of dry dimethylformamide and the mixture was stirred for 5 hours at room temperature. The solvent was evaporated in vacuo and 50 ml of dry dichloroethane were added to the residue and the mixture was concentrated in vacuo. The same procedure was repeated twice to remove excess thionyl chloride completely and to obtain an acid chloride.
[0024] The obtained acid chloride was dissolved in 50 ml of dry dichloroethane, and a solution of 9.97 g of N-[3-(3-pyridyl)propyl]-2,6-dimethylaniline in 5 ml of dry dichloroethane was dropped into the solution while keeping the temperature of the solution at 3-5°C. Following this the reaction mixture was stirred at room temperature over-night.
[0025] The precipitates were filtered off and washed twice each time with 50 ml of dry dichloroethane, the filtrate was concentrated in vacuo to give 22.6 g of (R)-2-phthalimido-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)-propyl]propanamide hydrochloride as an amorphous powder.
Optical purity: 98% ee
IR (KBr): νco 1715, 1660 cm⁻¹
Reference Example 3
(R)-2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide
[0026] To a solution of 22.6 g of (R)-2-phthalimido-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]-propanamide hydrochloride obtained in the Reference Example 2 in 113 ml of methanol was added 82 ml of 40% methylamine methanol solution and the reaction mixture was stirred overnight. The solvent was evaporated in vacuo, the residue was dissolved in 100 ml of 2N-hydrochloric acid and the solution was washed twice each time with 70 ml of methylenechloride. The aqueous layer was neutralized to pH 8 with sodium bicarbonate and the solution was extracted 3 times each time with 70 ml of methylene chloride.
[0027] The organic layer was washed with water and dried over anhydrous sodium sulfate and the solvent was evaporated in vacuo to give 8.4 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide.
Optical purity: 98% ee
IR (neat): νco 1650 cm⁻¹
Example 1
(R)-2-Amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl]propanamide D-tartrate
[0028] A mixture of 8.4 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide and 3.2 g of D-tartaric acid was dissolved in 33.5 ml of 3% aqueous ethanol and an authentic sample was seeded to the solution and the solution was allowed to stand overnight at room temperature.
[0029] The precipitated crystals were collected by filtration and dried under reduced pressure at 60°C to give 8.2g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide D-tartrate as white crystals.
Example 2
(R)-2-Amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl)propanamide dibenzoyl-D-tartrate
[0031] A mixture of 10 g of (RS)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide and 11.5 g of dibenzoyl D-tartaric acid were dissolved in 100 ml of ethanol and an authentic sample was seeded to the solution and the solution was allowed to stand overnight at 60°C. The precipitated crystals were collected by filtration and dried to give 9.92 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide dibenzoyl D-tartrate.
Yield: 46.1%; Optical purity: 92.6% ee
[0032] The crystals were dissolved in a mixed solvent of 100 ml of chloroform and 200 ml of ethanol and the solution was heated under reflux to remove chloroform completely. Ethanol was added to the residual mixture to prepare an ethanol solution of about 200 ml in volume and the solution was allowed to stand overnight at 60°C. The precipitated crystals were collected by filtration and dried to give 8,18 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide dibenzoyl D-tartrate.
Example 3
(R)-2-Amino-N-(2,6-dimethylphenyl)-N-(3-(3-pyridyl)propyl]propanamide D-tartrate
[0034] 50 ml of a saturated aqueous sodium bicarbonate solution was added to 8.18 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide dibenzoyl D-tartrate (optical purity: 100% ee) obtained in Example 2 and the mixture was extracted three times with 50 ml, 20 ml and 20 ml of methylene chloride.
[0035] The organic layer was washed successively with a saturated aqueous sodium bicarbonate solution and water and was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo to give 3.90 g of (R)-2-amin-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)-propyl]propanamide.
[0036] A mixture of 3.90 g of the free amine obtained above and 1.86 g of D-tartaric acid was dissolved in 15 ml of 3% aqueous ethanol and an authentic sample was seeded to the solution and the solution was allowed to stand overnight at room temperature.
[0037] The precipitated crystals were collected by filtration and dried to give 5.84 g of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide D-tartrate. The melting points and optical rotation of the product were identical to that of the compound prepared in Example 1.
Example 4
(R)-2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide di-p-toluoyl D-tartrate
[0039] A mixture of 500 mg of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide and 620 mg of di-p-toluoyl D-tartaric acid was dissolved in 5 ml of isopropanol and an authentic sample was seeded to the solution and the solution was allowed to stand overnight at room temperature. The precipitated crystals were collected by filtration and dried at 60°C to give 608 mg of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide di-p-toluoyl D-tartrate as white crystals.
Example 5
Hygroscopicities determination test
[0040] The hygroscopicities of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propanamide hydrochloride (hereinafter referred to as hydrochloride of the R-form compound); D-tartrate, dibenzoyl-D-tartrate and di-p-toluoyl D-tartrate of (R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)-propyl]propanamide (hereinafter referred to as D-tartrate of the R-form compound, dibenxoyl D-tartrate of the R-form compound and di-p-toluoyl D-tartrate of the R-form compound respectively), were determined as follows.
[0041] Each sample was weighed out in about 0.1 g or 0.2 g into a weighing dish having a diameter of about 2.7-3.0 cm.
[0042] The samples were allowed to stand in a constant moisturized vessel containing a saturated aqueous calcium nitrate solution and having 51% of relative humidity at about 25-26°C.
[0043] The change of weight on standing of each sample was measured and the hygroscopicity of each sample was determined according to the following equation.
W₁: Weight of the empty weighing dish (g)
W₂: Weight of the weighing dish containing a sample before standing (g)
W₃: Weight of the weighing dish containing a sample after standing (g)
1. An acid addition salt of an optically active alaninanilide compound represented by
the formula (I):
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group; and the carbon atom marked with (R) means a carbon atom in a form of R-configuration.
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group; and the carbon atom marked with (R) means a carbon atom in a form of R-configuration.
2. An acid addition salt of an optically active alaninanilide compound as claimed in
claim 1, represented by the formula (II):
wherein the carbon atom marked with (R) has the same meaning mentioned above.
wherein the carbon atom marked with (R) has the same meaning mentioned above.
3. A pharmaceutical composition for the treatment or arrhythmias, thrombosises or ischemic
cardiac insufficiencies in a mammal, which composition contains an effective dosage
of an acid addition salt of an optically active of an alaninanilide compound corresponding
to the formula represented in claim 1 or claim 2.
4. Use of an acid addition salt of an optically active alaninilide compound corresponding
to the formula represented in claim 1 or claim 2 in the preparation of a medicament
for the treatment of arrhythmias, thrombosises or ischemic cardiac insufficiencies
in a mammal.
Claims for the following Contracting State(s): ES
1. A method of preparing an acid addition salt of an optically active alaninanilide compound
represented by the formula (I):
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group, and the carbon atom marked with (R) means a carbon atom in a form of R-configuration, which comprises reacting a free amine of an optically active alaninanilide compound of formula (V)
with an optically active tartaric acid derivative selected from D-tartaric acid, dibenzoyl-D-tartaric acid and ditoluoyl-D-tartaric acid.
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group, and the carbon atom marked with (R) means a carbon atom in a form of R-configuration, which comprises reacting a free amine of an optically active alaninanilide compound of formula (V)
with an optically active tartaric acid derivative selected from D-tartaric acid, dibenzoyl-D-tartaric acid and ditoluoyl-D-tartaric acid.
2. A method of preparing an acid addition salt of an optically active alaninanilide compound
represented by the formula (I):
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group, and the carbon atom marked with (R) means a carbon atom in a form of R-configuration, which comprises reacting a free amine of a racemate of an alaninanilide compound of formula (IV)
with an optically active tartaric acid derivative selected from D-tartaric acid, dibenzoyl-D-tartaric acid and ditoluoyl-D-tartaric acid, followed by fractional crystallization of the obtained crude acid addition salt to yield the desired optically active salt.
wherein R¹ is a hydrogen atom, a benzoyl group or a toluoyl group, and the carbon atom marked with (R) means a carbon atom in a form of R-configuration, which comprises reacting a free amine of a racemate of an alaninanilide compound of formula (IV)
with an optically active tartaric acid derivative selected from D-tartaric acid, dibenzoyl-D-tartaric acid and ditoluoyl-D-tartaric acid, followed by fractional crystallization of the obtained crude acid addition salt to yield the desired optically active salt.
3. A method as claimed in claim 1 or claim 2 in which R¹ is a hydrogen atom.
4. A method as claimed in any one of claims I to 3 in which the reaction is carried out
in ethanol, aqueous ethanol, or isopropanol.